EGFR/CDK2-IN-3

EGFR/CDK2-IN-3

• UNSPSC Description: EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM[1].
• Target Antigen: CDK; EGFR
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/egfr-cdk2-in-3.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=CN(C2=CC=CC=C2)N=C1C3=NN4C(SC3)=NN=C4C5=CC=CC=C5)C6=CC=C7C=CC=CC7=C6
• Molecular Weight: 512.58
• References & Citations: [1]Salem M E, et al. Synthesis and Anti-Breast Cancer Potency of Mono-and Bis-(pyrazolyl [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors[J]. ACS Omega, 2023.. . .
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported